Literature DB >> 10425010

Low-dose protamine based on heparin-protamine titration method reduces platelet dysfunction after cardiopulmonary bypass.

O Shigeta1, H Kojima, Y Hiramatsu, T Jikuya, Y Terada, N Atsumi, Y Sakakibara, T Nagasawa, T Mitsui.   

Abstract

OBJECTIVE: The heparin-protamine titration method that uses the Hepcon hemostasis management system (Medtronic HemoTec Inc, Englewood, Colo) reduced blood loss in cardiac surgery in previous reports, but the mechanism is not fully understood. This study tests the hypothesis that reduced protamine administration preserves platelet function in human cardiac surgery.
METHODS: Platelet count, alpha-granule secretion, and aggregation to thrombin before and after cardiopulmonary bypass in human beings were evaluated. In the control group (n = 14), a fixed dose of protamine (3 mg/kg) was administered. In the titration group (n = 20), protamine doses were based on the heparin concentration measured by the Hepcon system.
RESULTS: Heparin concentrations before protamine administration were higher in the titration group (P =.0012), but protamine doses of patients in the titration group were markedly lower than those of the control group (P <.0001). During protamine infusion at a rate of 0.3 mg. kg(-1). min(-1), the percentage of granule membrane protein-140-positive platelets significantly increased in the control group compared with the titration group (18.8% +/- 8.6% vs 13.0% +/- 5.3%, P =.0188). After protamine administration, aggregation of washed platelets to thrombin recovered almost to the preoperative level in the titration group; however, it remained lower in the control group (20% +/- 20% vs 55% +/- 18%, P =.0009).
CONCLUSION: Low-dose administration of protamine, based on a heparin-protamine titration method, restores not only the blood coagulation but also the platelet responses to thrombin and attenuates platelet alpha-granule secretion during heparin neutralization. Overdose of protamine activates platelets and may predispose patients to excessive bleeding after cardiac surgery.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10425010     DOI: 10.1016/S0022-5223(99)70227-8

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  10 in total

Review 1.  The hemostatic defect of cardiopulmonary bypass.

Authors:  Matthew Dean Linden
Journal:  J Thromb Thrombolysis       Date:  2003-12       Impact factor: 2.300

Review 2.  [Management of hemostasis disorders after extracorporeal circulation. A clinical therapy algorithm].

Authors:  C Jámbor; D Bremerich; A Moritz; E Seifried; B Zwissler
Journal:  Anaesthesist       Date:  2008-04       Impact factor: 1.041

Review 3.  Are We Able to Dose Protamine Accurately Yet? A Review of the Protamine Conundrum.

Authors:  Patrick Hecht; Martin Besser; Florian Falter
Journal:  J Extra Corpor Technol       Date:  2020-03

4.  Can the Minimum Protamine Dose to Neutralize Heparin at the Completion of Cardiopulmonary Bypass be Significantly Lower than the Conventional Practice?

Authors:  Min-Ho Lee; William Riley; Kenneth G Shann
Journal:  J Extra Corpor Technol       Date:  2021-09

5.  STS/SCA/AmSECT Clinical Practice Guidelines: Anticoagulation during Cardiopulmonary Bypass.

Authors:  Linda Shore-Lesserson; Robert A Baker; Victor Ferraris; Philip E Greilich; David Fitzgerald; Philip Roman; John Hammon
Journal:  J Extra Corpor Technol       Date:  2018-03

Review 6.  Coagulation disorders of cardiopulmonary bypass: a review.

Authors:  Domenico Paparella; Stephanie J Brister; Michael R Buchanan
Journal:  Intensive Care Med       Date:  2004-07-24       Impact factor: 17.440

7.  Development of universal antidotes to control aptamer activity.

Authors:  Sabah Oney; Ruby T S Lam; Kristin M Bompiani; Charlene M Blake; George Quick; Jeremy D Heidel; Joanna Yi-Ching Liu; Brendan C Mack; Mark E Davis; Kam W Leong; Bruce A Sullenger
Journal:  Nat Med       Date:  2009-10-04       Impact factor: 53.440

8.  Heparin antagonism by polyvalent display of cationic motifs on virus-like particles.

Authors:  Andrew K Udit; Chris Everett; Andrew J Gale; Jennifer Reiber Kyle; Mihri Ozkan; M G Finn
Journal:  Chembiochem       Date:  2009-02-13       Impact factor: 3.164

9.  Nonclinical evaluation of novel cationically modified polysaccharide antidotes for unfractionated heparin.

Authors:  Bartlomiej Kalaska; Kamil Kaminski; Emilia Sokolowska; Dominik Czaplicki; Monika Kujdowicz; Krystyna Stalinska; Joanna Bereta; Krzysztof Szczubialka; Dariusz Pawlak; Maria Nowakowska; Andrzej Mogielnicki
Journal:  PLoS One       Date:  2015-03-17       Impact factor: 3.240

10.  Is There a "Blind Spot" in Point-of-Care Testing for Residual Heparin After Cardiopulmonary Bypass? A Prospective, Observational Cohort Study.

Authors:  Saskia Wand; Daniel Heise; Nadine Hillmann; Christian Bireta; Anselm Bräuer; Nicolas von Ahsen; Michael Quintel
Journal:  Clin Appl Thromb Hemost       Date:  2020 Jan-Dec       Impact factor: 2.389

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.